Spotlight Pathology

Investor: Liverpool City Region Seed Fund, UKI2S, Deepbridge, Lyva Labs, EHE Ventures, River Capital

Spotlight Pathology, a spinout from the University of Manchester, has secured a new investment of £1.4m to accelerate the commercial rollout of its AI cancer diagnostics product. This funding is critical for the company to transition its primary focus from technology development to supporting its products in clinical use, with initial deployments expected in NHS sites later this year.Summary of transaction details:Value: £1.4mSector: Health Technology, AI Cancer DiagnosticsAdvisor: None mentionedKey Entities: Target: Spotlight Pathology; Co-Lead Investors: Liverpool City Region Seed Fund, UKI2S; Additional Investors: Deepbridge, Lyva Labs, EHE Ventures, River CapitalLocation: Sci-Tech Daresbury (Target company base)Note: This investment is strategic for Spotlight Pathology as it moves beyond the development phase towards commercialization and clinical application of its AI lymphoma diagnostic device, addressing a critical need in healthcare through advanced technology.

Investor: Liverpool City Region Seed Fund and UKI2S

Spotlight Pathology, a University of Manchester spin‑out developing AI‑powered tools for blood cancer diagnostics, has secured £1.5 million in VC funding co‑led by Liverpool City Region Seed Fund and UKI2S, with continued support from existing investors including Deepbridge, Lyva Labs, EHE Ventures and River Capital. Summary of transaction details: Value: £1.5 million Sector: Healthcare & Biotech Advisor: Not disclosed Key Entities: Target – Spotlight Pathology; Lead Investors – Liverpool City Region Seed Fund, UKI2S Location: Sci‑Tech Daresbury, Cheshire, UK Note: The funding will accelerate the commercial rollout of Spotlight Pathology’s lymphoma diagnostic AI device, reflecting strong investor confidence in UK health‑tech innovation and the company’s growth trajectory within the NHS and private pathology markets.